Skip to main content

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE

Objective

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:
1. Optimizing local control by introducing novel radiation techniques resulting in redistribution of the radiation dose, creating inhomogeneous dose distribution towards the most active part of the tumour instead of conventional homogenous doses. This redistribution can be performed without increase of toxicity. As recently reported radiation accidents in the US demonstrate, QA is of outmost importance for safe radiation delivery in complex treatments. To assure accurate delivery over time, we will monitor both the patient’s geometry as well as the delivered dose using image guided adaptive plan modifications and 3D in-vivo dosimetric verification.
2. Maximizing the benefit of combined modality treatment
Both cisplatin and Cetuximab in combination with radiotherapy have shown to improve local control and survival but both drugs have severe side effects. As these drugs are not active in all patients, there is a large need to select patients which are sensitive to either drug. For this purpose the uptake of Cetuximab will be estimated by imaging tumour uptake with Zr89 labelled Cetuximab, while cisplatin sensitive tumours can be selected by biomarkers. This part was stopped in May 2014.
This proposal will:
1 optimise efficiency by selecting patients on treatment specific tumour response predictors and tailoring radiation to most active parts of the tumour.
2 improve quality of life by withholding ineffective, toxic treatments and redistribution of dose.
3 decrease community costs by reserving expensive treatments for those who will benefit.
This will be studied in randomized phase II clinical trials in top European institutes, followed by phase III trials outside this proposal.

Field of science

  • /natural sciences/mathematics/pure mathematics/geometry
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/head and neck cancer

Call for proposal

FP7-HEALTH-2010-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Address
Plesmanlaan 121
1066 CX Amsterdam
Netherlands
Activity type
Research Organisations
EU contribution
€ 2 347 168,15
Administrative Contact
Henri Van Luenen (Dr.)

Participants (14)

KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 424 688,80
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tina Dalianis (Prof.)
EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY
Belgium
EU contribution
€ 161 077,20
Address
Rue Martin V 40
1200 Bruxelles
Activity type
Other
Administrative Contact
Evelyn Chimfwembe (Ms.)
STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC
Netherlands
EU contribution
€ 937 130,40
Address
Dr. Tanslaan 12
6229 ET Maastricht
Activity type
Research Organisations
Administrative Contact
Florina Josephina Franssen (Ms.)
INSTITUT CATALA DE LA SALUT
Spain
EU contribution
€ 309 297,60
Address
Gran Via De Les Corts Catalanes 587
08007 Barcelona
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Lluis Masso (Mr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 685 575,60
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Audry Laurant (Ms.)
MAASTRO INNOVATIONS BV
Netherlands
EU contribution
€ 165 825
Address
Dr. Tanslaan 12
6229ET Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tiny De Vree (Ms.)
RAYSEARCH LABORATORIES AB (PUBL)
Sweden
EU contribution
€ 261 788,25
Address
Sveavagen 25
111 34 Stockholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Björn Hårdemark (Mr.)
THE CHRISTIE NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 78 384
Address
Wilmslow Road 1
M20 4BX Manchester
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Nicholas Slevin (Dr.)
INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 486 285,20
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
Administrative Contact
Arnauld Forest (Mr.)
STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
Address
Plesmanlaan 121
1066CX Amsterdam
Activity type
Research Organisations
Administrative Contact
Henri Van Luenen (Dr.)
REGION STOCKHOLM
Sweden
EU contribution
€ 33 188,40
Address
Hantverkargatan 45
104 22 Stockholm
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Christina Von Gertten (Dr.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 23 706
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
R. Castelijns
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 56 894,40
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rineke Van Der Neut (Mrs.)
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 23 706
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Johanna Van Apeldoorn (Ms.)